From a therapeutic perspective, engineering tumor antigen-specific CD8+ T cells to transiently overexpress miR-17-92 enhances their type-1 effector functions, including IFN-γ and TNF-α production, improves cytotoxic activity against target cells, and increases their capacity to control tumor growth in adoptive transfer models, suggesting potential applications in CAR-T cell therapy and tumor-infiltrating lymphocyte expansion protocols [87]. This evidence concerns the gene IFNG and neoplasm.